Get In Touch
Work Inquiries

THCV for the Management of Obesity and Diabetes

Did you know that most patients with type 2 diabetes are obese? The rising global prevalence of type 2 diabetes is driven by the obesity epidemic over the past 20 years. Canada’s obesity prevalence rate is 25.5%, ranking behind the United States (34.3%), Mexico (30%) and New Zealand (26.5%), and ahead of the United Kingdom (24%). Type 2 diabetes affects many major organs, including heart, blood vessels, nerves, eyes and kidneys. Other complications of type 2 diabetes may develop if the blood sugar is not kept under control overtime. These complications include hypoglycemia, diabetic ketoacidosis, heart and blood vessel diseases, high blood pressure, nerve damage, eye damage, kidney disease, hearing problems, skin problems, and in more serious conditions, coma and death.

A recent animal study showed that THCV decreased appetite, increased satiety, and up-regulated energy metabolism, making it a clinically useful remedy for weight loss and management of obesity and type 2 diabetic patients. In addition, THCV reduced fasting plasma glucose concentration in type 2 diabetics when compared to a placebo group. THCV is considered a potential candidate for the development of clinically useful therapies for managing obesity and diabetes.

Read more here: 




The freshest cannabis content, right to your inbox.

Sign up to receive the latest developments in cannabis science every week.

We don’t spam! Read our privacy policy for more info.

Author avatar
Dr. Dan Jin
Dr. Dan Jin is the resident Cannabis Research Scientist at PBG BioPharma. She has over 10 publications to her name in the field of cannabis research. She is a passionate force in researching novel uses of cannabis and educating the public about the potential of this incredible plant.

Post a comment

Your email address will not be published. Required fields are marked *

We use cookies to give you the best experience.